Table 3.
Multivariate analysis
| Factor | tPMC | CSS | LPFS | OS |
|---|---|---|---|---|
| P | p | p | p | |
| Primary site | ||||
| Metachronous or synchronous metastases | 0.147 (HR = 0.557; CI = 0.252–1.22) | |||
| Chemotherapy prior to SBRT | 0.109 (HR:2.65; CI = 0.803–8.75) | |||
| Primary controlled | 0.059 (HR:2.32; CI = 0.96–5.60) | |||
| Local control | 0.402 (HR = 0.735; CI = 0.359–1.75) | 0.59 (HR:0.772; CI = 0.338–0.637) | 0.414 (HR:0.724; CI = 0.332–1.58) | |
| Primary histology | ||||
| Gender | 0.161 (HR = 1.68; CI = 0.812–3.51) | 0.573 (HR:0.777; CI = 0.323–1.86) | 0.497 (HR:1.71;CI = 0.36–8.151) | 0.441 (HR:0.726; CI = 0.314–1.65) |
| Type of progression (oligo vs polymetastatic) | 0.003 (HR:0.276; CI = 0.120–0.637) | 0.014 (HR:0.386, CI = 0.181–0.824) | ||
| PTV < 44 cc | 0.048 (HR:0.293, CI = 0.087–0.987 |
tPMC time to polymetastatic conversion, CSS cancer-specific survival, LPFS local progression-free survival, OS overall survival